Phase 2/3 RCT: Tocilizumab in patients with new onset polymyalgia rheumatica.

Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial – Annals of Rheumatic Diseases (link to abstract – $ for full-text)

Commentary on Twitter

A 24 week RCT in patients with new-onset #PMR evaluating tocilizumab vs. placebo:
▶️ Primary Outcome: 63.2% of Toci vs. 11.8% in the PLC group reached glucocorticoid free remission at week 16
▶️ time to relapse: 130 days in Toci vs 82d in PLC grouphttps://t.co/4ylx2CqebR

— ARD & RMD Open (@ARD_BMJ) February 28, 2022